NO325273B1 - GLP-1-derivater - Google Patents

GLP-1-derivater Download PDF

Info

Publication number: NO325273B1
Authority: NO; Norway
Prior art keywords: glp; arg26; arg; lys; derivative according
Prior art date: 1996-08-30

Application number

NO19990950A

Other languages

English (en)

Norwegian (no)

Other versions

NO990950D0 (no

NO990950L (no

Inventor

Per Franklin Nielsen

Liselotte Bjerre Knudsen

Per Olaf Huusfeldt

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-30

Filing date

1999-02-26

Publication date

2008-03-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27221005&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO325273(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-02-26 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1999-02-26 Publication of NO990950D0 publication Critical patent/NO990950D0/no

1999-04-28 Publication of NO990950L publication Critical patent/NO990950L/no

2008-03-17 Publication of NO325273B1 publication Critical patent/NO325273B1/no

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract description 348
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims abstract description 59
102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 claims abstract description 51
125000001424 substituent group Chemical group 0.000 claims description 107
108090000765 processed proteins & peptides Proteins 0.000 claims description 69
125000000539 amino acid group Chemical group 0.000 claims description 60
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 43
125000003277 amino group Chemical group 0.000 claims description 33
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 31
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 27
108010016626 Dipeptides Proteins 0.000 claims description 23
101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 claims description 22
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 19
238000002360 preparation method Methods 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 13
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 13
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
229940079593 drug Drugs 0.000 claims description 10
125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 9
IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 claims description 8
125000002252 acyl group Chemical group 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 8
108010015792 glycyllysine Proteins 0.000 claims description 8
230000005923 long-lasting effect Effects 0.000 claims description 8
239000000825 pharmaceutical preparation Substances 0.000 claims description 8
102220209838 rs1057520382 Human genes 0.000 claims description 8
125000003275 alpha amino acid group Chemical group 0.000 claims description 7
230000002068 genetic effect Effects 0.000 claims description 7
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 5
208000008589 Obesity Diseases 0.000 claims description 4
230000007774 longterm Effects 0.000 claims description 4
235000020824 obesity Nutrition 0.000 claims description 4
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 3
102220290157 rs771847879 Human genes 0.000 claims description 3
101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 74
102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 74
101150118523 LYS4 gene Proteins 0.000 claims 1
TZLFWVPLPHJLSE-UHFFFAOYSA-N cyclopentane phenanthrene Chemical group C1CCCC1.C1=CC=C2C3=CC=CC=C3C=CC2=C1 TZLFWVPLPHJLSE-UHFFFAOYSA-N 0.000 claims 1
230000009471 action Effects 0.000 abstract description 5
230000000144 pharmacologic effect Effects 0.000 abstract description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 261
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 188
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 188
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 160
102100040918 Pro-glucagon Human genes 0.000 description 139
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 133
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 122
239000000243 solution Substances 0.000 description 97
239000000203 mixture Substances 0.000 description 95
239000011541 reaction mixture Substances 0.000 description 82
150000001875 compounds Chemical class 0.000 description 77
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 55
-1 enterogastrin Proteins 0.000 description 50
230000015572 biosynthetic process Effects 0.000 description 49
238000003786 synthesis reaction Methods 0.000 description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
238000006243 chemical reaction Methods 0.000 description 42
239000000047 product Substances 0.000 description 42
150000001793 charged compounds Chemical class 0.000 description 41
238000004987 plasma desorption mass spectroscopy Methods 0.000 description 41
239000004471 Glycine Substances 0.000 description 39
239000004205 dimethyl polysiloxane Substances 0.000 description 39
235000013870 dimethyl polysiloxane Nutrition 0.000 description 39
CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 39
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 39
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
238000004440 column chromatography Methods 0.000 description 36
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
239000000543 intermediate Substances 0.000 description 28
210000004027 cell Anatomy 0.000 description 22
101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 21
108010058003 Proglucagon Proteins 0.000 description 19
230000000694 effects Effects 0.000 description 19
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
102000035554 Proglucagon Human genes 0.000 description 16
102220604740 Lysosomal cobalamin transport escort protein LMBD1_G8K_mutation Human genes 0.000 description 15
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 14
239000008103 glucose Substances 0.000 description 14
239000008280 blood Substances 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
230000002473 insulinotropic effect Effects 0.000 description 13
230000028327 secretion Effects 0.000 description 13
239000013598 vector Substances 0.000 description 13
239000007864 aqueous solution Substances 0.000 description 12
238000000034 method Methods 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 11
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 9
239000005695 Ammonium acetate Substances 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
108060003199 Glucagon Proteins 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
150000001408 amides Chemical class 0.000 description 9
229940043376 ammonium acetate Drugs 0.000 description 9
235000019257 ammonium acetate Nutrition 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000000872 buffer Substances 0.000 description 9
238000010828 elution Methods 0.000 description 9
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 9
229940088597 hormone Drugs 0.000 description 9
239000005556 hormone Substances 0.000 description 9
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
102000051325 Glucagon Human genes 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
229960004666 glucagon Drugs 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
239000011734 sodium Substances 0.000 description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 6
230000003248 secreting effect Effects 0.000 description 6
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 5
108010076504 Protein Sorting Signals Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000003914 insulin secretion Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000000725 suspension Substances 0.000 description 5
101100335894 Caenorhabditis elegans gly-8 gene Proteins 0.000 description 4
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 4
241000282412 Homo Species 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
230000037406 food intake Effects 0.000 description 4
235000012631 food intake Nutrition 0.000 description 4
MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
239000002609 medium Substances 0.000 description 4
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
URJOZSLMTIRWFW-QGZVFWFLSA-N (4r)-4-(1,3-benzodioxol-5-yl)-5,6-dimethoxy-4,9-dihydro-1h-benzo[f][2]benzofuran-3-one Chemical compound C1=C2OCOC2=CC([C@H]2C3=C(COC3=O)CC3=CC=C(C(=C32)OC)OC)=C1 URJOZSLMTIRWFW-QGZVFWFLSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102400000320 Glicentin Human genes 0.000 description 3
101800002945 Glicentin Proteins 0.000 description 3
108010088406 Glucagon-Like Peptides Proteins 0.000 description 3
101800000221 Glucagon-like peptide 2 Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108010033276 Peptide Fragments Proteins 0.000 description 3
102000007079 Peptide Fragments Human genes 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108010086019 Secretin Proteins 0.000 description 3
102100037505 Secretin Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000010933 acylation Effects 0.000 description 3
238000005917 acylation reaction Methods 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000013024 dilution buffer Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 3
230000001369 glucagonostatic effect Effects 0.000 description 3
239000000859 incretin Substances 0.000 description 3
238000001802 infusion Methods 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
235000015097 nutrients Nutrition 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
229960002101 secretin Drugs 0.000 description 3
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
229960004906 thiomersal Drugs 0.000 description 3
238000001291 vacuum drying Methods 0.000 description 3
WSEVKKHALHSUMB-RYVRVIGHSA-N (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O WSEVKKHALHSUMB-RYVRVIGHSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
108010039627 Aprotinin Proteins 0.000 description 2
108010001478 Bacitracin Proteins 0.000 description 2
102400000113 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 2
102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
101800001226 Glicentin-related polypeptide Proteins 0.000 description 2
102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
229960004405 aprotinin Drugs 0.000 description 2
229960003071 bacitracin Drugs 0.000 description 2
229930184125 bacitracin Natural products 0.000 description 2
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000004992 fission Effects 0.000 description 2
230000030136 gastric emptying Effects 0.000 description 2
239000003629 gastrointestinal hormone Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 2
230000010030 glucose lowering effect Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000004347 intestinal mucosa Anatomy 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
OTNHQVHEZCBZQU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O OTNHQVHEZCBZQU-UHFFFAOYSA-N 0.000 description 1
ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 description 1
NZEDHZOVUDEBGW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O NZEDHZOVUDEBGW-UHFFFAOYSA-N 0.000 description 1
DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
108700040115 Adenosine deaminases Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000004452 Arginase Human genes 0.000 description 1
108700024123 Arginases Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
101800001982 Cholecystokinin Proteins 0.000 description 1
102100025841 Cholecystokinin Human genes 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 1
101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241001643667 Orpha Species 0.000 description 1
102400000319 Oxyntomodulin Human genes 0.000 description 1
101800001388 Oxyntomodulin Proteins 0.000 description 1
102400000050 Oxytocin Human genes 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108010079943 Pentagastrin Proteins 0.000 description 1
102100024819 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
101000829189 Staphylococcus aureus Glutamyl endopeptidase Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102000036693 Thrombopoietin Human genes 0.000 description 1
108010041111 Thrombopoietin Proteins 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
238000010640 amide synthesis reaction Methods 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
150000003931 anilides Chemical class 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229940107137 cholecystokinin Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003158 enteroendocrine cell Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
125000002642 gamma-glutamyl group Chemical group 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
108010014960 glicentin-related pancreatic peptide Proteins 0.000 description 1
UKVFVQPAANCXIL-FJVFSOETSA-N glp-1 (1-37) amide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 UKVFVQPAANCXIL-FJVFSOETSA-N 0.000 description 1
230000009229 glucose formation Effects 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
239000002303 hypothalamus releasing factor Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
210000002660 insulin-secreting cell Anatomy 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000000693 micelle Substances 0.000 description 1
210000000110 microvilli Anatomy 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000004899 motility Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
BFYLULHOYZNWPC-UHFFFAOYSA-N n-[[4,5-dimethyl-1-[(2-methylphenyl)methyl]imidazol-2-yl]methyl]-2,4-dimethoxy-n-(3-methylbutyl)benzamide Chemical compound COC1=CC(OC)=CC=C1C(=O)N(CCC(C)C)CC1=NC(C)=C(C)N1CC1=CC=CC=C1C BFYLULHOYZNWPC-UHFFFAOYSA-N 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000007230 neural mechanism Effects 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229960000444 pentagastrin Drugs 0.000 description 1
ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
102200071102 rs104894884 Human genes 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
238000002821 scintillation proximity assay Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

NO19990950A 1996-08-30 1999-02-26 GLP-1-derivater NO325273B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DK93196		1996-08-30
DK125996		1996-11-08
DK147096		1996-12-20
PCT/DK1997/000340 WO1998008871A1 (en)	1996-08-30	1997-08-22	Glp-1 derivatives

Publications (3)

Publication Number	Publication Date
NO990950D0 NO990950D0 (no)	1999-02-26
NO990950L NO990950L (no)	1999-04-28
NO325273B1 true NO325273B1 (no)	2008-03-17

Family

ID=27221005

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19990950A NO325273B1 (no)	1996-08-30	1999-02-26	GLP-1-derivater
NO2009027C NO2009027I2 (no)	1996-08-30	2009-11-18	Arg34Lys26(N epsilon-(gamma-glutamyl(N alfa-heksadecanoyl))-GLP-1-(7-37)
NO2019036C NO2019036I1 (no)	1996-08-30	2019-09-20	Liraglutid - forlenget SPC

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO2009027C NO2009027I2 (no)	1996-08-30	2009-11-18	Arg34Lys26(N epsilon-(gamma-glutamyl(N alfa-heksadecanoyl))-GLP-1-(7-37)
NO2019036C NO2019036I1 (no)	1996-08-30	2019-09-20	Liraglutid - forlenget SPC

Country Status (21)

Country	Link
EP (2)	EP0944648B1 (es)
JP (3)	JP3149958B2 (es)
KR (1)	KR100556067B1 (es)
CN (1)	CN1271086C (es)
AT (1)	ATE356830T1 (es)
BR (1)	BRPI9711437B8 (es)
CA (2)	CA2468374C (es)
CZ (1)	CZ300837B6 (es)
DE (3)	DE69737479D1 (es)
DK (1)	DK0944648T3 (es)
ES (1)	ES2283025T3 (es)
FR (1)	FR09C0054I2 (es)
HU (1)	HU227021B1 (es)
IL (3)	IL128332A0 (es)
NL (1)	NL300422I2 (es)
NO (3)	NO325273B1 (es)
PL (1)	PL192359B1 (es)
PT (1)	PT944648E (es)
RU (1)	RU2214419C2 (es)
UA (1)	UA72181C2 (es)
WO (1)	WO1998008871A1 (es)

Families Citing this family (478)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2262647C (en)	1996-08-08	2007-12-04	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US6268343B1 (en)	1996-08-30	2001-07-31	Novo Nordisk A/S	Derivatives of GLP-1 analogs
BRPI9711437B8 (pt) *	1996-08-30	2021-05-25	Novo Nordisk As	derivados de glp-1
US7235627B2 (en)	1996-08-30	2007-06-26	Novo Nordisk A/S	Derivatives of GLP-1 analogs
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
EP1840134B1 (en) *	1998-02-27	2016-04-13	Novo Nordisk A/S	GLP-1 derivatives
DE69942307D1 (de)	1998-02-27	2010-06-10	Novo Nordisk As	N-terminal veränderte glp-1 abkömmlinge
JP2002508162A (ja) *	1998-02-27	2002-03-19	ノボノルディスクアクティーゼルスカブ	Ｎ末端を短縮したｇｌｐ−１誘導体
EP1060191B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Derivatives of glp-1 analogs
JP2002504518A (ja) *	1998-02-27	2002-02-12	ノボノルディスクアクティーゼルスカブ	部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
EP1056775B1 (en)	1998-02-27	2010-04-28	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
CA2321026A1 (en)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2000007617A1 (en) *	1998-07-31	2000-02-17	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
US6720407B1 (en)	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
EP1666054A1 (en) *	1998-08-28	2006-06-07	Eli Lilly & Company	Method for administering insulinotropic peptides
CN1314818A (zh) *	1998-08-28	2001-09-26	伊莱利利公司	服用促胰岛素肽的方法
CN1317967A (zh)	1998-09-17	2001-10-17	伊莱利利公司	蛋白质制剂
MY155270A (en) *	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
CA2778047A1 (en) *	1998-12-07	2000-06-15	Ipsen Pharma S.A.S	Analogues of glp-1
RU2208015C2 (ru) *	1998-12-07	2003-07-10	Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас	Аналоги гпп-1
NZ527241A (en) *	1998-12-07	2004-12-24	Sod Conseils Rech Applic	Analogues of GLP-1
DE122007000001I1 (de) *	1999-01-14	2007-06-28	Amylin Pharmaceuticals Inc	Neue exendin agonist Formulierungen und deren Verabreichung
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
EP1163268B1 (en)	1999-03-15	2011-05-11	Novo Nordisk A/S	Ion exchange chromatographic separation of glp-1 and related peptides
KR20020002480A (ko) *	1999-03-17	2002-01-09	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	펩티드의 아실화법 및 신규한 아실화제
US6451974B1 (en)	1999-03-17	2002-09-17	Novo Nordisk A/S	Method of acylating peptides and novel acylating agents
ATE409193T1 (de) *	1999-03-17	2008-10-15	Novo Nordisk As	Verfahren zur acylierung von peptiden und proteinen
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
AU775063C (en) *	1999-04-30	2005-05-12	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US6329336B1 (en)	1999-05-17	2001-12-11	Conjuchem, Inc.	Long lasting insulinotropic peptides
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
WO2001035988A1 (en) *	1999-11-12	2001-05-25	Novo Nordisk A/S	Use of glp-1 agonists for the inhibition of beta cell degeneration
US6569832B1 (en)	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
US6844321B2 (en) *	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
JP2003525908A (ja)	2000-03-08	2003-09-02	ノボノルディスクアクティーゼルスカブ	血清脂質の低下
DE10013895A1 (de)	2000-03-21	2001-10-04	Dmc2 Degussa Metals Catalysts Cerdec Ag	Verfahren zur katalytischen Umsetzung von Kohlenmonoxid in einem Wasserstoff enthaltenden Gasgemisch
WO2002010195A2 (en) *	2000-08-02	2002-02-07	Theratechnologies Inc.	Modified peptides with increased potency
EP1346722B1 (en)	2000-12-01	2008-12-10	Takeda Pharmaceutical Company Limited	Method for producing preparation containing bioactive substance
WO2002046227A2 (en) *	2000-12-07	2002-06-13	Eli Lilly And Company	Glp-1 fusion proteins
CZ20031733A3 (cs)	2000-12-21	2003-09-17	Aventis Pharma Deutschland Gmbh	Difenylazetidinonové deriváty a farmaceutické prostředky s jejich obsahem
DK1345895T3 (da)	2000-12-21	2007-05-07	Sanofi Aventis Deutschland	Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser
WO2002069994A2 (en) *	2001-03-07	2002-09-12	Novo Nordisk A/S	Combined use of derivatives of glp-1 analogs and ppar ligands
US6573237B2 (en)	2001-03-16	2003-06-03	Eli Lilly And Company	Protein formulations
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE10142660A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6653492B2 (en)	2001-05-02	2003-11-25	Novo Nordick A/S	Preparation of bile acids
WO2002088166A1 (en) *	2001-05-02	2002-11-07	Novo Nordisk A/S	Preparation of bile acids
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE60224284T2 (de)	2001-06-28	2008-12-18	Novo Nordisk A/S	Stabile formulierung von modifiziertem glp-1
US7595172B2 (en) *	2001-07-24	2009-09-29	Novo Nordisk A/S	Method for making acylated polypeptides
US20030082671A1 (en)	2001-07-24	2003-05-01	Thomas Hoeg-Jensen	Method for making acylated polypeptides
MXPA04001328A (es)	2001-08-22	2004-05-05	Aventis Pharma Gmbh	Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
DE10142661B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
MXPA04001850A (es)	2001-08-31	2004-06-15	Aventis Pharma Gmbh	Derivados de diarilcicloalquilo, procedimientos para su preparacion y su utilizacion como agentes activadores de ppar.
DE10142659A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142665B4 (de)	2001-08-31	2004-05-06	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-one und ihre Derivate
DE10142663B4 (de)	2001-08-31	2004-08-19	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-ol-Systeme
DE10142666A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6884812B2 (en)	2001-08-31	2005-04-26	Aventis Pharma Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
DE10142668A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142722A1 (de)	2001-08-31	2003-03-27	Aventis Pharma Gmbh	C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7399777B2 (en)	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10142662B4 (de)	2001-08-31	2004-07-08	Aventis Pharma Deutschland Gmbh	Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142667B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE60230818D1 (de)	2001-09-24	2009-02-26	Imp Innovations Ltd	Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit
JP4563675B2 (ja)	2001-10-12	2010-10-13	ハイ・ポイント・ファーマスーティカルズ、エルエルシー	置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
KR20040054729A (ko) *	2001-10-18	2004-06-25	브리스톨-마이어스 스큅 컴퍼니	인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
BR0215212A (pt)	2001-12-21	2004-12-07	Novo Nordisk As	Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
EP1461069A2 (en)	2001-12-29	2004-09-29	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
AU2003200839B2 (en) *	2002-01-08	2008-12-11	Eli Lilly And Company	Extended glucagon-like peptide-1 analogs
US8058233B2 (en)	2002-01-10	2011-11-15	Oregon Health And Science University	Modification of feeding behavior using PYY and GLP-1
EP1474163A2 (en) *	2002-01-10	2004-11-10	Imperial College Innovations Limited	Modification of feeding behavior
CN1332711C (zh)	2002-02-20	2007-08-22	埃米球科技有限公司	施用glp－1分子的方法
US7223796B2 (en)	2002-04-11	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
US7049341B2 (en)	2002-06-07	2006-05-23	Aventis Pharma Deutschland Gmbh	N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
US7176194B2 (en)	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en)	2002-06-19	2007-02-13	Sanofi-Aventis Deutschland Gmbh	Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en)	2002-06-19	2010-03-02	Sanofi-Aventis Deutschland Gmbh	Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
KR101116627B1 (ko)	2002-06-27	2012-10-09	노보 노르디스크 에이/에스	치료제로서 아릴 카르보닐 유도체
DE60327771D1 (de) *	2002-07-04	2009-07-09	Zealand Pharma As	Glp-1 und behandlungsmethode für diabetes
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7262220B2 (en)	2002-07-11	2007-08-28	Sanofi-Aventis Deutschland Gmbh	Urea- and urethane-substituted acylureas, process for their preparation and their use
BR0312697A (pt)	2002-07-12	2005-04-26	Aventis Pharma Gmbh	Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento
US7141561B2 (en)	2002-07-25	2006-11-28	Sanofi-Aventis Deutschland Gmbh	Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US8821915B2 (en)	2002-08-09	2014-09-02	Veroscience, Llc	Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
EP1543030A2 (en)	2002-09-25	2005-06-22	Theratechnologies Inc.	Modified glp-1 peptides with increased biological potency
PL210455B1 (pl) *	2002-09-25	2012-01-31	Novo Nordisk As	Sposób otrzymywania acylowanych peptydów
US20040157922A1 (en)	2002-10-04	2004-08-12	Aventis Pharma Deutschland Gmbh	Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
US7208504B2 (en)	2002-10-12	2007-04-24	Sanofi-Aventis Deutschland Gmbh	Bicyclic inhibitors of hormone sensitive lipase
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
NZ541365A (en)	2002-12-27	2009-09-25	Diobex Inc	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en)	2002-12-27	2010-02-02	Diobex, Inc.	Compositions and methods for the prevention and control of insulin-induced hypoglycemia
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
US20040242583A1 (en)	2003-01-20	2004-12-02	Aventis Pharma Deutschland Gmbh	Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
US7179941B2 (en)	2003-01-23	2007-02-20	Sanofi-Aventis Deutschland Gmbh	Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE602004031927D1 (de)	2003-02-04	2011-05-05	Novo Nordisk As	Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
US7390814B2 (en)	2003-02-13	2008-06-24	Sanofi-Aventis Deutschland Gmbh	Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments
US7652007B2 (en)	2003-02-13	2010-01-26	Sanofi-Aventis Deutschland Gmbh	Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments
DE10306250A1 (de)	2003-02-14	2004-09-09	Aventis Pharma Deutschland Gmbh	Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7501440B2 (en)	2003-03-07	2009-03-10	Sanofi-Aventis Deutschland Gmbh	Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
JP4548335B2 (ja)	2003-03-07	2010-09-22	味の素株式会社	腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
PL1605897T3 (pl)	2003-03-19	2012-12-31	Lilly Co Eli	Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
JP4543236B2 (ja) *	2003-03-28	2010-09-15	独立行政法人農業生物資源研究所	組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
DE10314610A1 (de)	2003-04-01	2004-11-04	Aventis Pharma Deutschland Gmbh	Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
EP1615698B1 (en)	2003-04-11	2010-09-29	High Point Pharmaceuticals, LLC	New amide derivatives and pharmaceutical use thereof
CA2820537C (en)	2003-04-23	2015-10-20	Valeritas, Inc.	Hydraulically actuated pump for fluid administration
WO2004105790A1 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
CN102940879B (zh)	2003-06-03	2017-06-06	诺沃挪第克公司	稳定化的药物肽组合物
WO2005019261A1 (en)	2003-08-21	2005-03-03	Novo Nordisk A/S	Separation of polypeptides comprising a racemized amino acid
WO2005023291A2 (en) *	2003-09-11	2005-03-17	Novo Nordisk A/S	Use of glp1-agonists in the treatment of patients with type i diabetes
CN100444898C (zh) *	2003-09-19	2008-12-24	诺沃挪第克公司	治疗肽的清蛋白结合型衍生物
US20060287221A1 (en)	2003-11-13	2006-12-21	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005046716A1 (en) *	2003-11-13	2005-05-26	Novo Nordisk A/S	Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
CN104826116A (zh)	2003-11-20	2015-08-12	诺沃挪第克公司	对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP1694356B1 (en)	2003-12-09	2011-02-16	Novo Nordisk A/S	Regulation of food preference using glp-1 agonists
EP1694278A4 (en)	2003-12-16	2009-08-12	Ipsen Pharma	GLP-1 PHARMACEUTICAL COMPOSITIONS
CA2551039C (en) *	2003-12-16	2013-01-29	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Analogues of glp-1
RU2006120079A (ru)	2003-12-18	2008-01-27	Ново Нордиск А/С (DK)	Производные глюкагоноподобного пептида-1 (glp-1)
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
DK1723128T3 (da)	2004-01-06	2013-02-18	Novo Nordisk As	Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
AU2005203925A1 (en) *	2004-01-08	2005-07-21	Theratechnologies Inc.	Glucagon-Like Peptide-1 analogs with long duration of action
ES2397241T3 (es)	2004-01-21	2013-03-05	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
US7241787B2 (en)	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
US7498341B2 (en)	2004-01-31	2009-03-03	Sanofi Aventis Deutschland Gmbh	Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7470706B2 (en)	2004-01-31	2008-12-30	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en)	2004-01-31	2008-07-22	Sanofi-Aventis Deutschland Gmbh,	7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004005172A1 (de)	2004-02-02	2005-08-18	Aventis Pharma Deutschland Gmbh	Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
KR100564618B1 (ko)	2004-03-11	2006-03-28	삼성전자주식회사	디스크 드라이브의 층간 탐색 방법
GT200500063A (es)	2004-04-01	2005-10-14		Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
EP1586573B1 (en)	2004-04-01	2007-02-07	Sanofi-Aventis Deutschland GmbH	Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1604988A1 (en)	2004-05-18	2005-12-14	Sanofi-Aventis Deutschland GmbH	Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN1950078A (zh)	2004-06-11	2007-04-18	诺和诺德公司	使用glp－1激动剂抵抗药物诱发的肥胖
US9089636B2 (en)	2004-07-02	2015-07-28	Valeritas, Inc.	Methods and devices for delivering GLP-1 and uses thereof
ES2442223T3 (es)	2004-08-31	2014-02-10	Novo Nordisk A/S	Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
EP1841749A1 (en)	2004-09-02	2007-10-10	Metabasis Therapeutics, Inc.	Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
JP2008515856A (ja) *	2004-10-07	2008-05-15	ノボノルディスクアクティーゼルスカブ	遅延性ｇｌｐ−１化合物
JP5107713B2 (ja)	2004-10-07	2012-12-26	ノヴォノルディスクアー／エス	遅延性のエキセンディン−４化合物
CN106137952B (zh)	2004-11-12	2020-11-17	诺和诺德公司	促胰岛素肽的稳定制剂
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
CA2590720A1 (en)	2004-12-03	2006-06-08	Lone Jeppesen	Heteroaromatic glucokinase activators
TWI376234B (en)	2005-02-01	2012-11-11	Msd Oss Bv	Conjugates of a polypeptide and an oligosaccharide
US20080171695A1 (en)	2005-02-02	2008-07-17	Novo Nordisk A/S	Insulin Derivatives
WO2006082204A1 (en)	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
WO2006097538A1 (en)	2005-03-18	2006-09-21	Novo Nordisk A/S	Extended glp-1 compounds
TWI372629B (en) *	2005-03-18	2012-09-21	Novo Nordisk As	Acylated glp-1 compounds
US8840586B2 (en)	2006-08-23	2014-09-23	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
US7641649B2 (en)	2005-05-06	2010-01-05	Medtronic Minimed, Inc.	Reservoir support and method for infusion device
US8512288B2 (en)	2006-08-23	2013-08-20	Medtronic Minimed, Inc.	Infusion medium delivery device and method with drive device for driving plunger in reservoir
US7905868B2 (en)	2006-08-23	2011-03-15	Medtronic Minimed, Inc.	Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8277415B2 (en)	2006-08-23	2012-10-02	Medtronic Minimed, Inc.	Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8137314B2 (en)	2006-08-23	2012-03-20	Medtronic Minimed, Inc.	Infusion medium delivery device and method with compressible or curved reservoir or conduit
US20080097291A1 (en)	2006-08-23	2008-04-24	Hanson Ian B	Infusion pumps and methods and delivery devices and methods with same
EP1889618A4 (en) *	2005-05-27	2010-11-24	Daiichi Sankyo Co Ltd	COMBINED MEDICINE FOR THE TREATMENT OF DIABETES
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
AU2006265172B2 (en)	2005-06-30	2011-09-15	Vtv Therapeutics Llc	Phenoxy acetic acids as PPAR delta activators
AU2006264966B2 (en)	2005-07-04	2013-02-21	High Point Pharmaceuticals, Llc	Histamine H3 receptor antagonists
JP4960355B2 (ja)	2005-07-14	2012-06-27	ノボ・ノルデイスク・エー／エス	ウレア型グルコキナーゼ活性化剤
ES2426345T3 (es)	2005-07-20	2013-10-22	Eli Lilly And Company	Compuesto unidos en posición 1-amino
DK1767545T3 (da) *	2005-09-22	2010-03-15	Biocompatibles Uk Ltd	GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
PL1951658T3 (pl)	2005-11-17	2013-02-28	Lilly Co Eli	Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
JP5096363B2 (ja)	2005-12-16	2012-12-12	ネクターセラピューティックス	Ｇｌｐ−１のポリマ複合体
EP2386540A1 (en)	2005-12-22	2011-11-16	High Point Pharmaceuticals, LLC	Novel compounds, their preparation and use
MX2008009125A (es)	2006-01-18	2008-10-23	Qps Llc	Composiciones farmaceuticas con estabilidad mejorada.
US11478623B2 (en)	2006-02-09	2022-10-25	Deka Products Limited Partnership	Infusion pump assembly
CA2641569C (en)	2006-02-09	2015-10-06	Deka Products Limited Partnership	Fluid delivery systems and methods
US11497846B2 (en)	2006-02-09	2022-11-15	Deka Products Limited Partnership	Patch-sized fluid delivery systems and methods
US11027058B2 (en)	2006-02-09	2021-06-08	Deka Products Limited Partnership	Infusion pump assembly
US11364335B2 (en)	2006-02-09	2022-06-21	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
ES2427247T3 (es)	2006-03-13	2013-10-30	Kyorin Pharmaceutical Co., Ltd.	Aminoquinolonas como inhibidores de GSK-3
EP1996224B1 (en)	2006-03-15	2012-11-07	Novo Nordisk A/S	Mixtures of amylin and insulin
KR101280333B1 (ko)	2006-03-28	2013-07-02	하이 포인트 파마슈티칼스, 엘엘씨	히스타민 ｈ３ 수용체 활성을 갖는 벤조티아졸
ES2566058T3 (es)	2006-03-30	2016-04-08	Valeritas, Inc.	Dispositivo de suministro de fluidos de múltiples cartuchos
WO2007127704A1 (en)	2006-04-24	2007-11-08	Eli Lilly And Company	Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ATE444741T1 (de)	2006-05-10	2009-10-15	Biocompatibles Uk Ltd	Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
CA2659570C (en)	2006-05-29	2015-10-06	High Point Pharmaceuticals, Llc	3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
KR101466933B1 (ko)	2006-07-11	2014-12-01	큐피에스 엘엘씨	펩타이드의 지속 방출 전달을 위한 의약 조성물
EP2049567A2 (en)	2006-07-18	2009-04-22	Centocor, Inc.	Human glp-1 mimetibodies, compositions, methods and uses
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7828764B2 (en)	2006-08-23	2010-11-09	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
US7794434B2 (en)	2006-08-23	2010-09-14	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
US7455663B2 (en)	2006-08-23	2008-11-25	Medtronic Minimed, Inc.	Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US7811262B2 (en)	2006-08-23	2010-10-12	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir filling and infusion medium delivery
ES2531934T3 (es)	2006-09-01	2015-03-20	Novo Nordisk Health Care Ag	Glicoproteínas modificadas
MX2009002282A (es)	2006-09-07	2009-03-20	Nycomed Gmbh	Tratamiento de combinacion para diabetes mellitius.
ES2377322T3 (es)	2006-11-15	2012-03-26	High Point Pharmaceuticals, Llc	Nuevas 2-(2-hidroxifenil)benzotiadiazinas útiles para el tratamiento de la obesidad y la diabetes
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
AU2008204530B2 (en)	2007-01-11	2013-08-01	Vtv Therapeutics Llc	Urea glucokinase activators
DE102007002260A1 (de)	2007-01-16	2008-07-31	Sanofi-Aventis	Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
DE102007005045B4 (de)	2007-01-26	2008-12-18	Sanofi-Aventis	Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
EP1975176A1 (en) *	2007-03-27	2008-10-01	Biocompatibles UK Limited	Novel glp-1 fusion peptides, their production and use
US8613725B2 (en)	2007-04-30	2013-12-24	Medtronic Minimed, Inc.	Reservoir systems and methods
US7963954B2 (en)	2007-04-30	2011-06-21	Medtronic Minimed, Inc.	Automated filling systems and methods
US8323250B2 (en)	2007-04-30	2012-12-04	Medtronic Minimed, Inc.	Adhesive patch systems and methods
US8597243B2 (en)	2007-04-30	2013-12-03	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir air bubble management
US8434528B2 (en)	2007-04-30	2013-05-07	Medtronic Minimed, Inc.	Systems and methods for reservoir filling
US7959715B2 (en)	2007-04-30	2011-06-14	Medtronic Minimed, Inc.	Systems and methods allowing for reservoir air bubble management
DK2146760T3 (en)	2007-04-30	2019-01-28	Medtronic Minimed Inc	FILLING OF RESERVOIR, BUBBLE MANAGEMENT AND DELIVERY SYSTEMS FOR INFUSION MEDIA AND PROCEDURES
CA2963857A1 (en)	2007-06-04	2008-12-11	Ben-Gurion University Of The Negev Research And Development Authority	Tri-aryl compounds and compositions comprising the same
US20080319221A1 (en)	2007-06-22	2008-12-25	Bernd Junker	Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
JP2009019027A (ja) *	2007-07-16	2009-01-29	Hanmi Pharmaceutical Co Ltd	アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CN101743252A (zh)	2007-07-16	2010-06-16	诺沃-诺迪斯克有限公司	蛋白酶稳定化的、peg化的胰岛素类似物
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2679597A1 (en)	2007-09-05	2014-01-01	Novo Nordisk A/S	Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2190460B1 (en)	2007-09-05	2014-12-17	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
CN101842386A (zh) *	2007-09-05	2010-09-22	诺沃-诺迪斯克有限公司	截短的glp-1衍生物和它们的治疗用途
ES2371800T3 (es)	2007-09-11	2012-01-10	Kyorin Pharmaceutical Co.,Ltd.	Cianoaminoquinolonas como inhibidores de gsk-3.
BRPI0816814B1 (pt)	2007-09-12	2021-08-31	Kyorin Pharmaceutical Co. Ltd	Composto, composição farmacêutica e uso de um composto
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
ES2430042T3 (es)	2007-11-16	2013-11-18	Novo Nordisk A/S	Composiciones farmacéuticas estables que comprenden liraglutida y degludec
US20100317057A1 (en)	2007-12-28	2010-12-16	Novo Nordisk A/S	Semi-recombinant preparation of glp-1 analogues
US9456955B2 (en)	2007-12-31	2016-10-04	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
US10188787B2 (en)	2007-12-31	2019-01-29	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
MX2010007324A (es)	2007-12-31	2010-09-30	Deka Products Lp	Ensamble de bomba de infusion.
US8900188B2 (en)	2007-12-31	2014-12-02	Deka Products Limited Partnership	Split ring resonator antenna adapted for use in wirelessly controlled medical device
CA2711244C (en)	2007-12-31	2016-02-16	Deka Products Limited Partnership	Infusion pump assembly
US8881774B2 (en)	2007-12-31	2014-11-11	Deka Research & Development Corp.	Apparatus, system and method for fluid delivery
US10080704B2 (en)	2007-12-31	2018-09-25	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
BRPI0907119A2 (pt)	2008-01-09	2015-07-14	Sanofi Aventis Deutschland	Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de)	2008-05-24	2009-11-26	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DK2229407T3 (en)	2008-01-09	2017-02-27	Sanofi Aventis Deutschland	NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
EP2259791A2 (en) *	2008-03-05	2010-12-15	Tel HaShomer Medical Research Infrastructure and Services Ltd.	Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
WO2009115469A1 (en)	2008-03-18	2009-09-24	Novo Nordisk A/S	Protease stabilized, acylated insulin analogues
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
CN101555214B (zh)	2008-04-08	2012-07-11	北京嘉事联博医药科技有限公司	苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
EP3412300A1 (en)	2008-06-27	2018-12-12	Duke University	Therapeutic agents comprising elastin-like peptides
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
CA2733200A1 (en)	2008-08-06	2010-02-11	Novo Nordisk Health Care Ag	Conjugated proteins with prolonged in vivo efficacy
CN102149411A (zh)	2008-09-12	2011-08-10	诺沃—诺迪斯克有限公司	酰化肽或蛋白的方法
CA3132517C (en)	2008-09-15	2024-04-30	Deka Products Limited Partnership	Systems and methods for fluid delivery
DE102008051834A1 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
WO2010043566A2 (de)	2008-10-17	2010-04-22	Sanofi-Aventis Deutschland Gmbh	Kombination von einem insulin und einem glp-1-agonisten
DE102008053048A1 (de)	2008-10-24	2010-04-29	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de)	2009-08-20	2011-03-03	Sanofi-Aventis Deutschland Gmbh	Kombination von einem Insulin und einem GLP-1-Agonisten
DK2344519T3 (en)	2008-11-07	2017-01-23	Massachusetts Gen Hospital	C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
IT1392655B1 (it)	2008-11-20	2012-03-16	Bio Ker S R L	Site-specific monoconjugated insulinotropic glp-1 peptides.
AU2009316802B2 (en)	2008-11-21	2015-02-26	Vtv Therapeutics Llc	Adamantyl benzamide compounds
JP5759379B2 (ja)	2008-12-05	2015-08-05	アンジオケムインコーポレーテッド	ニューロテンシンまたはニューロテンシンアナログおよびその使用
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EA020520B1 (ru)	2008-12-15	2014-11-28	Зилэнд Фарма А/С	Аналоги глюкагона
CN102282166B (zh)	2008-12-15	2015-04-01	西兰制药公司	胰高血糖素类似物
DK2370462T3 (da)	2008-12-15	2014-09-08	Zealand Pharma As	Glucagon-analoger
EP2370459A1 (en)	2008-12-15	2011-10-05	Zealand Pharma A/S	Glucagon analogues
CN102292349B (zh)	2009-01-22	2016-04-13	诺沃—诺迪斯克保健股份有限公司	稳定的生长激素化合物
US9480753B2 (en)	2009-01-23	2016-11-01	Novo Nordisk A/S	FGF21 derivatives with albumin binder A-B-C-D-E- and their use
CN102942626B (zh) *	2009-03-05	2015-11-04	江苏豪森医药集团有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
WO2010104205A1 (en)	2009-03-11	2010-09-16	Kyorin Pharmaceutical Co., Ltd.	7-cycloalkylaminoquinolones as gsk-3 inhibitors
AU2014265118B2 (en) *	2009-06-05	2016-11-17	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
EP2437732B1 (en) *	2009-06-05	2018-05-09	VeroScience LLC	Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US9352025B2 (en)	2009-06-05	2016-05-31	Veroscience Llc	Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CN102802657A (zh) *	2009-06-11	2012-11-28	诺沃-诺迪斯克有限公司	用于治疗2型糖尿病的glp-1和fgf21组合
SG177609A1 (en)	2009-07-13	2012-02-28	Zealand Pharma As	Acylated glucagon analogues
JP5961111B2 (ja)	2009-07-15	2016-08-02	デカ・プロダクツ・リミテッド・パートナーシップ	注入ポンプアセンブリのための装置、システム、および方法
CN101987868B (zh) *	2009-07-30	2013-09-04	江苏豪森医药集团有限公司	Glp-1类似物的衍生物或其可药用盐和用途
US8614182B2 (en)	2009-07-30	2013-12-24	Jiangsu Hansoh Pharmaceuticals Co., Ltd.	GLP-1 analogues and their pharmaceutical salts and uses
CN102612376A (zh)	2009-08-06	2012-07-25	诺沃-诺迪斯克保健股份有限公司	具有延长的体内功效的生长激素
CA2771278A1 (en)	2009-08-26	2011-03-03	Sanofi	Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2482823A2 (en)	2009-10-02	2012-08-08	Sanofi	Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases
US20120264685A1 (en)	2009-10-22	2012-10-18	Rajesh Bahekar	Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
US9707176B2 (en)	2009-11-13	2017-07-18	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical composition comprising a GLP-1 agonist and methionine
ES2855146T3 (es)	2009-11-13	2021-09-23	Sanofi Aventis Deutschland	Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
WO2011080102A2 (en)	2009-12-16	2011-07-07	Novo Nordisk A/S	Glp-1 analogues and derivatives
CN106139158A (zh)	2010-01-22	2016-11-23	诺沃—诺迪斯克保健股份有限公司	体内功效延长的生长激素
JP5844280B2 (ja)	2010-01-22	2016-01-13	デカ・プロダクツ・リミテッド・パートナーシップ	形状記憶合金ワイヤ制御のための方法およびシステム
EP2525833A2 (en)	2010-01-22	2012-11-28	Novo Nordisk Health Care AG	Stable growth hormone compounds
US20130012432A1 (en)	2010-02-26	2013-01-10	Novo Nordisk A/S	Peptides for Treatment of Obesity
BR112012021231A2 (pt)	2010-02-26	2015-09-08	Basf Plant Science Co Gmbh	método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2542565A1 (en) *	2010-03-01	2013-01-09	Novo Nordisk A/S	Preparative rp-hplc method for purifying peptides
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2559320C2 (ru)	2010-03-26	2015-08-10	Ново Нордиск А/С	Новые аналоги глюкагона
WO2011123943A1 (en)	2010-04-09	2011-10-13	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
DE102010015123A1 (de)	2010-04-16	2011-10-20	Sanofi-Aventis Deutschland Gmbh	Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MX343360B (es)	2010-04-27	2016-11-03	Zealand Pharma As	Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
KR20130093470A (ko)	2010-04-30	2013-08-22	가부시키가이샤산와카가쿠켄큐쇼	생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
MX2012014961A (es)	2010-06-24	2013-02-26	Zealand Pharma As	Analogos de glucagon.
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
PT2611458T (pt)	2010-08-30	2016-12-16	Sanofi Aventis Deutschland	Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
US9040481B2 (en)	2010-11-02	2015-05-26	The General Hospital Corporation	Methods for treating steatotic disease
JP6039569B2 (ja)	2010-11-09	2016-12-07	ノヴォノルディスクアー／エス	二重アシル化されたｇｌｐ−１誘導体
RU2600440C3 (ru)	2010-12-16	2021-12-10	Ново Нордиск А/С	Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
EP2665469A1 (en)	2011-01-19	2013-11-27	Novo Nordisk A/S	Glp-1 compositions
JP2014502985A (ja)	2011-01-19	2014-02-06	ノヴォノルディスクアー／エス	Ｇｌｐ−１粒子および組成物
UY33872A (es)	2011-01-20	2012-08-31	Zealand Pharma As	Uso de análogos de glucagón acilados
EP2670368A4 (en)	2011-02-03	2015-04-15	Pharmedica Ltd	NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
AU2012234276A1 (en)	2011-03-28	2013-08-29	Novo Nordisk A/S	Novel glucagon analogues
CN106117344B (zh)	2011-04-12	2020-11-03	诺沃—诺迪斯克有限公司	双酰化glp-1衍生物
WO2012150503A2 (en)	2011-05-03	2012-11-08	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en)	2011-05-10	2012-11-15	Zealand Pharma A/S	Glu-glp-1 dual agonist signaling-selective compounds
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2729157B1 (en)	2011-07-06	2019-01-16	The General Hospital Corporation	A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
PT2750699E (pt)	2011-08-29	2015-11-03	Sanofi Aventis Deutschland	Acelerómetro pendular
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013029279A1 (zh) *	2011-09-03	2013-03-07	深圳市健元医药科技有限公司	新的glp-ⅰ类似物及其制备方法和用途
EP2753642B8 (en)	2011-09-06	2017-12-13	Novo Nordisk A/S	Glp-1 derivatives
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TWI596110B (zh)	2011-09-23	2017-08-21	諾佛儂迪克股份有限公司	新穎升糖素類似物
TW201315742A (zh)	2011-09-26	2013-04-16	Novartis Ag	治療代謝病症之雙功能蛋白質
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2763690B1 (en)	2011-10-04	2015-11-25	Sanofi-Aventis Deutschland GmbH	Lixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
WO2013050378A1 (en)	2011-10-04	2013-04-11	Sanofi-Aventis Deutschland Gmbh	Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
CN104144704B (zh)	2011-11-03	2018-03-23	西兰制药公司	Glp‑1受体激动剂肽胃泌素缀合物
WO2013083826A2 (en)	2011-12-09	2013-06-13	Novo Nordisk A/S	Glp-1 agonists
ES2682253T3 (es)	2011-12-29	2018-09-19	Novo Nordisk A/S	Dipéptido que comprende un aminoácido no proteogénico
US9663568B2 (en)	2012-02-15	2017-05-30	Novo Nordisk A/S	Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
ES2640268T3 (es)	2012-02-15	2017-11-02	Novo Nordisk A/S	Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
WO2013134519A2 (en)	2012-03-07	2013-09-12	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
HRP20231613T1 (hr)	2012-03-22	2024-03-15	Novo Nordisk A/S	Pripravci koji sadrže sredstvo za unošenje i njihova priprava
US10933120B2 (en)	2012-03-22	2021-03-02	Novo Nordisk A/S	Compositions of GLP-1 peptides and preparation thereof
EP2844670B1 (en)	2012-05-03	2017-12-06	Zealand Pharma A/S	Glucagon-like-peptide-2 (glp-2) analogues
IN2014MN02304A (es)	2012-05-03	2015-08-07	Zealand Pharma As
US11274135B2 (en) *	2012-05-08	2022-03-15	Novo Nordisk A/S	Double-acylated GLP-1 derivatives
JP6250034B2 (ja) *	2012-05-08	2017-12-20	ノヴォノルディスクアー／エス	二重アシル化されたｇｌｐ−１誘導体
EP2664374A1 (en) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
EP2863895B1 (en)	2012-06-20	2021-04-14	Novo Nordisk A/S	Tablet formulation comprising a peptide and a delivery agent
MX366405B (es)	2012-07-01	2019-07-08	Novo Nordisk As	Uso de peptidos glp-1 de accion prolongada.
JP6224586B2 (ja)	2012-07-10	2017-11-01	武田薬品工業株式会社	注射用製剤
AR091866A1 (es)	2012-07-23	2015-03-04	Zealand Pharma As	Analogos del glucagon
FR2994848B1 (fr)	2012-08-30	2014-08-22	Univ Paris Curie	Traitement de l'arthrose par les hormones incretines ou leurs analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2908844A1 (en)	2012-10-17	2015-08-26	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
IN2015DN03795A (es)	2012-10-24	2015-10-02	Inserm Inst Nat De La Santé Et De La Rech Médicale
WO2014093696A2 (en)	2012-12-12	2014-06-19	Massachusetts Institute Of Technology	Insulin derivatives for diabetes treatment
ES2688367T3 (es)	2012-12-21	2018-11-02	Sanofi	Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
CN103059127B (zh) *	2013-01-07	2014-12-17	天津嘉宏科技有限公司	Glp-1类似物及其制备方法与应用
EP2968471B1 (en)	2013-03-01	2017-07-19	Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca	Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
EP2968443B1 (en)	2013-03-15	2021-09-29	Protagonist Therapeutics, Inc.	Hepcidin analogues and uses thereof
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
WO2014170496A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
CA3130345A1 (en)	2013-07-03	2015-01-08	Deka Products Limited Partnership	Apparatus, system and method for fluid delivery
US10266577B2 (en)	2013-08-15	2019-04-23	Novo Nordisk A/S	GLP-1 derivatives, and uses thereof
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
UA122767C2 (uk)	2013-10-17	2021-01-06	Зіленд Фарма А/С	Ацильований аналог глюкагону
JP6657101B2 (ja)	2013-11-05	2020-03-04	ベングリオンユニバーシティオブザネガフリサーチアンドディベロップメントオーソリティ	糖尿病及びそれから生じる疾患合併症の治療のための化合物
CA2929459C (en)	2013-11-06	2022-05-03	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
EA035688B1 (ru)	2013-11-06	2020-07-27	Зилэнд Фарма А/С	Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
CN103884846B (zh) *	2014-03-06	2016-06-08	杭州九源基因工程有限公司	一种利拉鲁肽生物学活性的检测方法
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
WO2015155151A1 (en) *	2014-04-07	2015-10-15	Novo Nordisk A/S	Double-acylated glp-1 compounds
TWI668010B (zh)	2014-05-07	2019-08-11	丹麥商諾佛儂迪克股份有限公司	使用ｇｌｐ－１及抗ｉｌ－２１治療糖尿病
NZ726337A (en)	2014-05-16	2023-10-27	Protagonist Therapeutics Inc	Α4β7 integrin thioether peptide antagonists
CN106536547A (zh)	2014-06-04	2017-03-22	诺和诺德股份有限公司	用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN104987383A (zh) *	2014-07-08	2015-10-21	四川百利药业有限责任公司	一种glp-1衍生物
GB2528436A (en)	2014-07-15	2016-01-27	Lancaster Univ Business Entpr Ltd	Treatment of neurological diseases
CA2955460A1 (en)	2014-07-17	2016-01-21	Protagonist Therapeutics, Inc.	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
KR20240029114A (ko)	2014-07-17	2024-03-05	노보 노르디스크 에이/에스	점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
EP3530671A3 (en)	2014-09-05	2019-11-13	University of Copenhagen	Gip peptide analogues
JP2017535527A (ja)	2014-10-01	2017-11-30	プロタゴニストセラピューティクス，インコーポレイテッド	新規のα４β７ペプチド単量体及び二量体拮抗薬
EP3201217A4 (en)	2014-10-01	2018-07-18	Protagonist Therapeutics Inc.	Novel cyclic monomer and dimer peptides having integrin antagonist activity
EP3006045B3 (en)	2014-10-07	2021-03-17	Cyprumed GmbH	Pharmaceutical formulations for the oral delivery of peptide or protein drugs
BR112017008659A2 (pt)	2014-10-29	2018-01-30	Zealand Pharma As	?métodos e compostos de agonista de gip?
ES2739289T3 (es)	2014-11-27	2020-01-30	Novo Nordisk As	Derivados de GLP-1 y sus usos
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
RU2729011C2 (ru)	2014-12-23	2020-08-03	Ново Нордиск А/С	Производные fgf21 и их применения
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
AU2016232218B2 (en)	2015-03-18	2020-09-10	Boehringer Ingelheim International Gmbh	Amylin analogues
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10426818B2 (en)	2015-03-24	2019-10-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Method and pharmaceutical composition for use in the treatment of diabetes
AU2016247499B2 (en)	2015-04-16	2020-09-03	Zealand Pharma A/S	Acylated glucagon analogue
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10787490B2 (en)	2015-07-15	2020-09-29	Protaganist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA2997343A1 (en)	2015-10-07	2017-04-13	Cyprumed Gmbh	Pharmaceutical formulations for the oral delivery of peptide drugs
US20190002503A1 (en)	2015-12-30	2019-01-03	Protagonist Therapeutics, Inc.	Analogues of hepcidin mimetics with improved in vivo half lives
EP3205660A1 (en)	2016-02-10	2017-08-16	Polypeptide Laboratories Holding (PPL) AB	Method for preparation of peptides with pswang linker
EP3196206A1 (en)	2016-01-20	2017-07-26	Lonza Ltd	Method for preparation of liraglutide
WO2017127007A1 (en)	2016-01-20	2017-07-27	Poypeptide Laboratories Holding (Ppl) Ab	METHOD FOR PREPARATION OF PEPTIDES WITH psWANG LINKER
EP3205664A1 (en)	2016-02-11	2017-08-16	Polypeptide Laboratories Holding (PPL) AB	Method for preparation of liraglutide using bal linker
JP7053480B2 (ja)	2016-03-03	2022-04-12	ノヴォノルディスクアー／エス	Ｇｌｐ－１誘導体及びその使用
CN108883158A (zh)	2016-03-04	2018-11-23	诺和诺德股份有限公司	用于肾脏病况的利拉鲁肽
US20190070266A1 (en)	2016-03-04	2019-03-07	Novo Nordisk A/S	Liraglutide in Diabetic Foot Ulcer
US11117946B2 (en)	2016-03-23	2021-09-14	Bachem Holding Ag	Method for preparing glucagon-like peptides
CA3017926C (en)	2016-03-23	2023-10-10	Protagonist Therapeutics, Inc.	Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2017162653A1 (en)	2016-03-23	2017-09-28	Bachem Holding Ag	Purification of glucagon-like peptide 1 analogs
US10071140B2 (en)	2016-09-09	2018-09-11	Zealand Pharma A/S	Amylin analogues
US20190224122A1 (en)	2016-09-23	2019-07-25	Delpor, Inc.	Stable compositions for incretin mimetic compounds
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN110022935A (zh)	2016-11-28	2019-07-16	诺和诺德股份有限公司	用于心血管病况的德谷胰岛素
CN110099719A (zh)	2016-11-28	2019-08-06	诺和诺德股份有限公司	用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素
WO2018096164A1 (en)	2016-11-28	2018-05-31	Novo Nordisk A/S	Insulin degludec for treating diabetes
WO2018104263A1 (en)	2016-12-06	2018-06-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
WO2018104558A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en)	2016-12-09	2018-06-14	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
CN117384274A (zh)	2016-12-09	2024-01-12	西兰制药公司	酰化的glp-1/glp-2双重激动剂
AU2017373901B2 (en)	2016-12-09	2021-06-03	Zealand Pharma A/S	GLP-1/GLP-2 dual agonists
GB201621987D0 (en)	2016-12-22	2017-02-08	Archer Virgil L See Archer Sheri A Arecor Ltd	Novel composition
CN111032680A (zh)	2017-03-15	2020-04-17	诺和诺德股份有限公司	能够与黑皮质素4受体结合的双环化合物
WO2018210919A1 (en)	2017-05-17	2018-11-22	Novo Nordisk A/S	Glp-1 compositions and uses thereof
BR112019025195A8 (pt)	2017-05-31	2020-07-07	Univ Copenhagen	análogos do peptídeo gip de ação prolongada
TWI762706B (zh)	2017-08-24	2022-05-01	丹麥商諾佛儂迪克股份有限公司	Glp-1組成物及其用途
JP2020533302A (ja)	2017-09-10	2020-11-19	ノヴォノルディスクアー／エス	肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
TW201920234A (zh)	2017-09-11	2019-06-01	美商領導醫療有限公司	類鴉片促效劑肽及其用途
WO2019120480A1 (en)	2017-12-19	2019-06-27	Novo Nordisk A/S	Solubility of glp-1 peptide
EP3746111B1 (en)	2018-02-02	2023-07-19	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CA3089868A1 (en)	2018-02-08	2019-08-15	Protagonist Therapeutics, Inc.	Conjugated hepcidin mimetics
KR20200135797A (ko)	2018-02-27	2020-12-03	제트피 에스피브이 3 케이/에스	콤프스타틴 유사체 및 이들의 의학적 용도
AR117566A1 (es)	2018-04-02	2021-08-18	Bristol Myers Squibb Co	Anticuerpos anti-trem-1 y sus usos
SG11202009467YA (en)	2018-04-05	2020-10-29	Sun Pharmaceutical Ind Ltd	Novel glp-1 analogues
US20210087250A1 (en)	2018-04-06	2021-03-25	Cyprumed Gmbh	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019200594A1 (zh)	2018-04-19	2019-10-24	杭州先为达生物科技有限公司	酰化的glp-1衍生物
WO2019209963A1 (en)	2018-04-24	2019-10-31	Deka Products Limited Partnership	Apparatus and system for fluid delivery
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2019219714A1 (en)	2018-05-15	2019-11-21	Novo Nordisk A/S	Compounds capable of binding to melanocortin 4 receptor
WO2019222072A1 (en) *	2018-05-15	2019-11-21	Savior Lifetec Corporation	Preparation method of liraglutide derivative
US10905738B2 (en)	2018-07-05	2021-02-02	Biozeus Desenvolvimento De Produtos Biofarmacêuticos	Synthetic peptides, prodrugs, pharmaceutical compositions and uses
WO2020053414A1 (en)	2018-09-14	2020-03-19	Novo Nordisk A/S	Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
US20220298218A1 (en)	2018-12-03	2022-09-22	Antag Therapeutics Aps	Modified GIP Peptide Analogues
EP3938037A1 (en)	2019-03-15	2022-01-19	Diet4Life ApS	Combination of dietary peptides
WO2020201280A1 (en)	2019-04-01	2020-10-08	Novo Nordisk A/S	Antibodies directed against liraglutide and use thereof
EP3997105A4 (en)	2019-07-10	2023-09-13	Protagonist Therapeutics, Inc.	PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
KR20220066287A (ko)	2019-08-27	2022-05-24	제트피 에스피브이 3 케이/에스	콤프스타틴 유사체 및 이의 의약 용도
CA3154744A1 (en)	2019-11-06	2021-05-14	Sarah FRIEDRICH	Glp-1 receptor agonists in dementia
US20220395559A1 (en)	2019-11-07	2022-12-15	Novo Nordisk A/S	Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2021105393A1 (en)	2019-11-29	2021-06-03	Novo Nordisk A/S	Processes for obtaining stable glp-1 compositions
CN111040022B (zh)	2019-12-23	2021-12-14	万新医药科技(苏州)有限公司	针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
CA3166496A1 (en)	2019-12-30	2021-07-08	Gan & Lee Pharmaceuticals Co., Ltd.	Long-acting glp-1 compound
CA3167751A1 (en)	2020-01-15	2021-07-22	Janssen Biotech, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021144476A1 (en)	2020-02-18	2021-07-22	Novo Nordisk A/S	Pharmaceutical formulations
WO2021198196A1 (en)	2020-03-30	2021-10-07	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
EP4126004A1 (en)	2020-03-30	2023-02-08	Zealand Pharma A/S	Agonist combination
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
CN115461044A (zh)	2020-04-29	2022-12-09	诺和诺德股份有限公司	包含glp-1激动剂和组氨酸的固体组合物
EP4146221A1 (en)	2020-05-07	2023-03-15	Frederiksberg Hospital	Treatment of hyperuricemia
WO2022049310A1 (en)	2020-09-07	2022-03-10	Cyprumed Gmbh	Improved pharmaceutical formulations of glp-1 receptor agonists
EP4222176A4 (en) *	2020-09-30	2024-02-28	Beijing Ql Biopharmaceutical Co Ltd	POLYPEPTIDE CONJUGATES AND METHODS OF USE
PE20240631A1 (es)	2020-11-20	2024-03-26	Janssen Pharmaceutica Nv	Composiciones de inhibidores peptidicos del receptor de interleucina-23
EP4281034A1 (en)	2021-01-24	2023-11-29	Forrest, Michael, David	Inhibitors of atp synthase - cosmetic and therapeutic uses
FR3120189A1 (fr)	2021-03-01	2022-09-02	Farid Bennis	Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
WO2023285334A1 (en)	2021-07-12	2023-01-19	Novo Nordisk A/S	Novel fatty acid modified urocortin 2 derivatives and the uses thereof
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations
WO2023031380A1 (en)	2021-09-03	2023-03-09	Zealand Pharma A/S	Dosage regime
WO2023038039A1 (ja)	2021-09-08	2023-03-16	塩野義製薬株式会社	抗肥満作用の関与する疾患の予防及び治療用医薬
WO2023192873A1 (en) *	2022-03-28	2023-10-05	Bristol-Myers Squibb Company	Macrocyclic immunomodulators
WO2024061919A1 (en)	2022-09-19	2024-03-28	Zealand Pharma A/S	Combination therapy
WO2024068848A1 (en)	2022-09-28	2024-04-04	Zealand Pharma A/S	Methods for treating obesity
EP4345104A1 (en)	2022-09-30	2024-04-03	Bachem Holding AG	Method for preparing liraglutide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
CA1341320C (en)	1986-05-05	2001-11-20	Joel Habener	Insulinotropic hormone
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
DE69129226T2 (de) *	1990-01-24	1998-07-30	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
DK36492D0 (da)	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
GB9409496D0 (en) *	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
BRPI9711437B8 (pt) *	1996-08-30	2021-05-25	Novo Nordisk As	derivados de glp-1

1997
- 1997-08-22 BR BRPI9711437A patent/BRPI9711437B8/pt not_active IP Right Cessation
- 1997-08-22 DE DE69737479A patent/DE69737479D1/de not_active Expired - Lifetime
- 1997-08-22 ES ES97935509T patent/ES2283025T3/es not_active Expired - Lifetime
- 1997-08-22 JP JP51118398A patent/JP3149958B2/ja not_active Expired - Lifetime
- 1997-08-22 KR KR1019997001750A patent/KR100556067B1/ko active Protection Beyond IP Right Term
- 1997-08-22 CN CNB971984131A patent/CN1271086C/zh not_active Expired - Lifetime
- 1997-08-22 IL IL12833297A patent/IL128332A0/xx active IP Right Grant
- 1997-08-22 DE DE69737479T patent/DE69737479T4/de not_active Expired - Lifetime
- 1997-08-22 PL PL331896A patent/PL192359B1/pl unknown
- 1997-08-22 CZ CZ0062999A patent/CZ300837B6/cs not_active IP Right Cessation
- 1997-08-22 EP EP97935509A patent/EP0944648B1/en not_active Expired - Lifetime
- 1997-08-22 PT PT97935509T patent/PT944648E/pt unknown
- 1997-08-22 DE DE122009000079C patent/DE122009000079I2/de active Active
- 1997-08-22 UA UA99021142A patent/UA72181C2/uk unknown
- 1997-08-22 CA CA2468374A patent/CA2468374C/en not_active Expired - Lifetime
- 1997-08-22 EP EP07103319A patent/EP1826216A1/en not_active Withdrawn
- 1997-08-22 WO PCT/DK1997/000340 patent/WO1998008871A1/en active Application Filing
- 1997-08-22 RU RU99106518/04A patent/RU2214419C2/ru active Protection Beyond IP Right Term
- 1997-08-22 CA CA002264243A patent/CA2264243C/en not_active Expired - Lifetime
- 1997-08-22 AT AT97935509T patent/ATE356830T1/de active
- 1997-08-22 DK DK97935509T patent/DK0944648T3/da active
- 1997-08-22 HU HU9903714A patent/HU227021B1/hu active Protection Beyond IP Right Term
1999
- 1999-02-02 IL IL128332A patent/IL128332A/en active Protection Beyond IP Right Term
- 1999-02-26 NO NO19990950A patent/NO325273B1/no not_active IP Right Cessation
2000
- 2000-05-19 JP JP2000152778A patent/JP2001011095A/ja active Pending
2006
- 2006-07-24 JP JP2006201324A patent/JP2006348038A/ja active Pending
2008
- 2008-01-30 IL IL189136A patent/IL189136A/en not_active IP Right Cessation
2009
- 2009-10-22 NL NL300422C patent/NL300422I2/nl unknown
- 2009-10-23 FR FR09C0054C patent/FR09C0054I2/fr active Active
- 2009-11-18 NO NO2009027C patent/NO2009027I2/no unknown
2019
- 2019-09-20 NO NO2019036C patent/NO2019036I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU3847897A (en)	1998-03-19
IL189136A (en)	2015-05-31
IL128332A0 (en)	2000-01-31
BR9711437A (pt)	2000-01-18
DE122009000079I2 (de)	2011-06-16
NL300422I2 (nl)	2010-04-01
AU732957C (en)	1998-03-19
FR09C0054I2 (fr)	2011-04-01
DE69737479T4 (de)	2010-05-06
HU227021B1 (en)	2010-05-28
NO2019036I1 (no)	2019-09-20
CA2468374C (en)	2010-12-21
CN1271086C (zh)	2006-08-23
HUP9903714A3 (en)	2000-07-28
RU2214419C2 (ru)	2003-10-20
HUP9903714A2 (hu)	2000-03-28
JP2000500505A (ja)	2000-01-18
FR09C0054I1 (es)	2009-04-12
CA2264243C (en)	2004-10-05
DE69737479D1 (de)	2007-04-26
ATE356830T1 (de)	2007-04-15
EP0944648A1 (en)	1999-09-29
CN1232470A (zh)	1999-10-20
JP2006348038A (ja)	2006-12-28
NO2009027I1 (no)	2009-11-30
PL331896A1 (en)	1999-08-16
EP0944648B1 (en)	2007-03-14
IL189136A0 (en)	2008-06-05
AU732957B2 (en)	2001-05-03
EP1826216A1 (en)	2007-08-29
DK0944648T3 (da)	2007-07-02
UA72181C2 (uk)	2005-02-15
PL192359B1 (pl)	2006-10-31
JP2001011095A (ja)	2001-01-16
WO1998008871A1 (en)	1998-03-05
CA2264243A1 (en)	1998-03-05
KR20000035964A (ko)	2000-06-26
JP3149958B2 (ja)	2001-03-26
DE69737479T2 (de)	2007-11-29
NL300422I1 (nl)	2010-01-04
NO2009027I2 (no)	2015-01-19
NO990950D0 (no)	1999-02-26
KR100556067B1 (ko)	2006-03-07
ES2283025T3 (es)	2007-10-16
CA2468374A1 (en)	1998-03-05
PT944648E (pt)	2007-06-26
IL128332A (en)	2008-04-13
DE122009000079I1 (de)	2010-05-27
BRPI9711437B1 (pt)	2017-05-16
CZ62999A3 (cs)	1999-07-14
CZ300837B6 (cs)	2009-08-26
BRPI9711437B8 (pt)	2021-05-25
NO990950L (no)	1999-04-28

Legal Events

Date	Code	Title	Description
2007-04-02	CREP	Change of representative	Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS
2015-01-19	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: LIRAGLUTID; REG. NO/DATE: EU/1/09/529/001-005 20090804 FIRST REG. NO/DATE: EU/1/09/529/001-005 20090630 Spc suppl protection certif: 2009027 Filing date: 20091118 Extension date: 20220822
2017-09-11	MK1K	Patent expired
2019-09-30	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: LIRAGLUTID - FORLENGET SPC; REG. NO/DATE: EU/1/12/830/001-002 20130701 Spc suppl protection certif: 2019036 Filing date: 20190920
2021-01-18	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: LIRAGLUTID - FORLENGET SPC; REG. NO/DATE: EU/1/12/830/001-002 20130701 Spc suppl protection certif: 2019036 Filing date: 20190920 Extension date: 20230222
2022-09-12	SPCX	Expiry of an spc	Spc suppl protection certif: 2009027

Publication	Publication Date	Title
NO325273B1 (no)	2008-03-17	GLP-1-derivater
EP1056775B1 (en)	2010-04-28	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1060191B1 (en)	2010-04-28	Derivatives of glp-1 analogs
EP1061946B1 (en)	2004-04-28	Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
US6268343B1 (en)	2001-07-31	Derivatives of GLP-1 analogs
US6458924B2 (en)	2002-10-01	Derivatives of GLP-1 analogs
US8097698B2 (en)	2012-01-17	Derivatives of GLP-1 analogs
AU3847897C1 (en)	2018-08-02	GLP-1 derivatives
EP1840134B1 (en)	2016-04-13	GLP-1 derivatives
MXPA99001823A (es)	1999-09-01	Derivados de glp-1